儿童及青少年泌乳素瘤的临床特征与结局:一项大型回顾性队列研究
该研究回顾性分析北京协和医院2012至2021年诊断时年龄≤20岁的170例泌乳素瘤患者(女115例、男55例,中位年龄16.6岁)。男孩及青春期早期诊断的女孩肿瘤更大、泌乳素水平更高。多巴胺激动剂为一线治疗,耐药率22.5%;手术总体长期缓解率32.9%,非侵袭性肿瘤达59.4%。
要点
- 男孩及青春期早期诊断的女孩泌乳素瘤临床特征更严重。
- 多巴胺激动剂一线治疗耐药率22.5%,与最大肿瘤直径独立相关(P=0.035)。
- 手术长期缓解率非侵袭性肿瘤59.4%,侵袭性肿瘤仅5.0%。
核心结论
- 儿童及青少年泌乳素瘤在男孩及青春期早期诊断的患者中临床特征更严重。
- 鉴于药物使泌乳素正常化的总体疗效及非侵袭性肿瘤可观的手术缓解率,多巴胺激动剂仍为儿童及青少年泌乳素瘤的一线推荐,而手术可能适用于非侵袭性肿瘤。
研究设计与样本
- 回顾性分析北京协和医院2012至2021年诊断时年龄≤20岁的泌乳素瘤患者队列。
- 队列共170例(女115例、男55例,中位年龄16.6岁)。
主要发现
- 20.0%(23/115)的女孩无月经初潮,33.3%(18/54)的男孩处于青春期前。
- 中位最大直径为15.0 mm(大腺瘤61.2%,巨大腺瘤4.6%),中位基线泌乳素水平为211.0 ng/mL。
- 诊断时无月经初潮的女孩及男孩肿瘤更大、泌乳素水平更高。
- 大多数女孩以月经紊乱就诊(86.7%),男孩常受头痛(42.6%)、身高增长速度减慢(25.9%)及青春期延迟(18.2%)困扰。
- 133例患者以多巴胺激动剂为一线治疗,耐药率为22.5%(25/111),与最大肿瘤直径独立相关(P=0.035)。
关键数值与推荐
- 76例患者接受手术,总体长期手术缓解率为32.9%(25/76),与海绵窦侵袭独立负相关(P=0.025)。
- 非侵袭性肿瘤手术缓解率为59.4%(19/32),其中25例非侵袭性大腺瘤为64.0%。
- 侵袭性肿瘤手术缓解率为5.0%(1/20)。
临床怎么用
- 多巴胺激动剂仍为儿童及青少年泌乳素瘤的一线推荐。
- 手术可能适用于非侵袭性肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prolactinoma, the most common subtype of pituitary adenoma, is rare in children and adolescents. Clinical presentation and treatment outcomes of prolactinomas in this population have been evaluated insufficiently. OBJECTIVE: To summarize the clinical features, both medication and surgical outcomes of prolactinomas in children and adolescents in a large retrospective cohort from China. METHODS: A cohort of patients with prolactinomas aged ≤20 years at diagnosis between 2012 and 2021 in Peking Union Medical College Hospital were retrospectively analyzed. RESULTS: The cohort comprised 170 patients (115 females and 55 males, median age 16.6 years), with 20.0% (23/115) girls without menarche and 33.3% (18/54) boys in prepuberty. The median maximal diameter was 15.0 mm (61.2% macroadenomas and 4.6% giant adenomas), and the median baseline prolactin (PRL) level was 211.0 ng/mL. Larger sizes and higher PRL levels were observed in girls without menarche at diagnosis and in boys. Most girls presented with menstrual disturbance (86.7%), and boys were frequently bothered by headaches (42.6%), reduced height velocities (25.9%), and delayed puberty (18.2%). Dopamine agonists (DAs) were used as first-line treatment in 133 patients, and the resistance rate was 22.5% (25/111), independently associated with maximal tumor diameters (P = .035). Surgery was performed in 76 patients. Long-term surgical remission rates were 32.9% (25/76) overall, negatively associated with cavernous sinus invasion independently (P = .025), 59.4% (19/32) in noninvasive tumors (64.0% in 25 noninvasive macroadenomas), and 5.0% (1/20) in invasive tumors. CONCLUSION: Pediatric prolactinomas exhibited more severe clinical characteristics in boys and in patients diagnosed during earlier stages of pubertal developments. Given the overall efficacy of PRL normalization by medication and considerable surgical remission rate in noninvasive tumors, DAs remain the first-line recommendation for prolactinomas in children and adolescents, while surgery might be viable for noninvasive tumors.
引用
- Yang Y, Ke X, Duan L, et al. Clinical Characteristics and Outcomes of Prolactinomas in Children and Adolescents: A Large Retrospective Cohort Study. J Clin Endocrinol Metab. 2024. PMID: 38164002. doi:10.1210/clinem/dgad769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。